. 2021 Apr 22;12(5):629. doi: 10.3390/genes12050629

Table 2.

Least square means and their standard errors for the effect of Nano-Ag treatment (20 and 40 ppm) on the expression of myogenic determination factor 1 (MYOD1), myogenic factor 5 (MYF5), myogenic factor 6 (MYF6), myogenin (MYOG), and myocyte enhancer factor 2A (MEF2A) on days (D) 5, 8, and 18 of incubation. The expression is presented in fold change compared with the non-injected control, (n = 3, from each group).

Groups	MYOD1 *			MYF5 *			MYF6 *			MYOG *			MEF2A *
Groups	D 5	D 8	D 18	D 5	D 8	D 18	D 5	D 8	D 18	D 5	D 8	D 18	D 5	D 8	D 18
Non-injected control	1.00 ^a ± 0.00	1.00 ^b ± 0.00	1.00 ^b ± 0.00	1.00 ^a ± 0.00	1.00 ^b ± 0.00	1.00 ^ab ± 0.00	1.00 ^c ± 0.00	1.00 ^b ± 0.00	1.00 ^a ± 0.00	1.00 ^a ± 0.00	1.00 ^a ± 0.00	1.00 ^a ± 0.00	1.00 ^a ± 0.00	1.00 ^a ± 0.00	1.00 ^a ± 0.00
20 ppm	2.44 ^a ± 1.16	4.65 ^a ± 0.90	1.53 ^a ± 0.18	1.32 ^a ± 0.96	6.19 ^a ± 2.37	0.79 ^ab ± 0.18	5.00 ^ab ± 0.47	11.61 ^a ± 1.13	1.30 ^a ± 0.16	1.32 ^a ± 0.18	0.92 ^a ± 0.14	0.79 ^a ± 0.09	0.54 ^a ± 0.48	0.73 ^ab ± 0.29	1.20 ^a ± 0.22
40 ppm	0.65 ^a ± 0.08	3.25 ^ab ± 1.19	1.31 ^ab ± 0.19	1.52 ^a ± 0.50	2.39 ^ab ± 0.21	1.62 ^a ± 0.39	5.49 ^a ± 0.70	8.33 ^a ± 0.84	1.46 ^a ± 0.08	1.18 ^a ± 0.31	0.76 ^a ± 0.09	0.91 ^a ± 0.17	0.90 ^a ± 0.14	0.39 ^bc ± 0.05	1.13 ^a ± 0.38

* Means in the same column with the same superscript letters are not significant (one-way analysis of variance (ANOVA), p > 0.05). a and b superscripts indicate significant differences between means.